Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biological Markers Evaluated for Early Cervical Cancer Diagnosis

By LabMedica International staff writers
Posted on 27 Jun 2013
A method for the early diagnosis and prognosis of cervical cancer has been investigated which may lead to potential gene therapy biological targets. More...


The expression of the anti-oncogene phosphatase and tensin (PTEN) homologue and survivin in the progression of cervical neoplasia has been elucidated based on clinic-pathological features in squamous cell carcinoma of the uterine cervix.

Scientists at the Yangzhou University Medical College (China) enrolled for a study 20 patients with cervical ectropion and squamous metaplasia, 30 with cervical intraepithelial neoplasia, and 49 with cervical squamous cell carcinoma between January 2010 and August 2011. Normal cervical epithelium from 10 people served as the control. Immunohistochemical staining was performed to detect PTEN and survivin expression in each group using a streptavidin kit (Zhongshan Golden Bridge Biotechnology, Beijing, China).

The investigators found that PTEN expression progressively decreased with the continuum from normal epithelium to squamous cell carcinoma, whereas survivin expression progressively increased. Furthermore, positive PTEN immunostaining was associated with clinical stage and tumor size. The level of PTEN expression in the metastatic pelvic lymph node group was significantly lower compared with the nonmetastatic pelvic lymph node group. Positive survivin immunostaining was associated with clinical stage and tumor size. Survivin-positive expression in the metastatic pelvic lymph node group was significantly higher compared with the nonmetastatic pelvic lymph node group.

The PTEN gene acts as a tumor suppressor gene through the action of its phosphatase protein product, while survivin is a protein encoded by the antiapoptotic gene baculoviral inhibitor of apoptosis repeat containing 5 (BIRC5). The authors concluded that positive expression levels of PTEN and survivin provide potential evaluation indices for early diagnosis and prognosis of uterine cervical cancer, and these biomarkers are also potentially promising therapeutic targets. The study was published in the June 2013 online edition of the journal the British Journal of Biomedical Science.

Related Links:

Yangzhou University Medical College
Zhongshan Golden Bridge Biotechnology



New
Gold Member
Automatic CLIA Analyzer
Shine i9000
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A blood biomarker test offers a clearer prognosis after cardiac arrest (Photo courtesy of Adobe Stock)

Blood Biomarker Improves Early Brain Injury Prognosis After Cardiac Arrest

After a cardiac arrest, many patients remain unconscious for days, leaving doctors and families facing uncertainty about whether meaningful recovery is possible. Current tools to assess brain damage, including... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.